Survival of advanced epithelial ovarian/fallopian tube/primary peritoneum carcinoma after high-complexity upper abdominal surgery

Objective: To analyze the survival effects of upper abdominal procedures (UAPs) in patients with the International Federation of Gy-necology and Obstetrics (FIGO) Stage IIIb to IV ovarian cancer stratified by initial presence of upper abdominal disease (UAD) and UAP performance. Materials and Methods: The authors retrospectively reviewed records of patients with FIGO Stage IIIb to IV epithelial ovarian cancer confirmed by pathology between January 2007 and December 2016 from the gynecologic cancer registry of Kangbuk Samsung Hospital. Results: During the study period, 74 patients with FIGO Stage IIIb to IV epithelial ovarian cancer underwent primary cytoreductive surgery. Among them, 28 patients had no UAD and no UAPs (group 1), 30 had UAD but did not undergo complete UAPs, especially without diaphragmatic resection (group 2), and 16 had UAD and underwent complete UAP including diaphragmatic resection (group 3). Except for age, most baseline characteristics did not vary among the three groups. In group 3, diaphragm peritonectomy was the most commonly performed UAP (93.8%), followed by liver resection (6.8%) with significant differences between groups 2 and 3 (p < 0.01). Five-year OS was 77.9% in group 1, 9.5% in group 2, and 76.7% in group 3 (p < 0.01). Median PFS was 37 months in group 1, 10 months in group 2, and 25 months in group 3 (p < 0.01). Conclusions: UAPs including complete removal of diaphragmatic lesions led to better survival outcomes for advanced-stage ovarian cancer.

Advanced-stage ovarian cancer; Upper abdominal surgery; Survival.

[1] Jemal A., Murray T., Samuels A., Ghafoor A., Ward E., Thun M.J.: “Cancer statistics, 2003”. CA Cancer J. Clin., 2003, 53, 5.

[2] Rodriguez N., Miller A., Richard S.D., Rungruang B., Hamilton C.A., Bookman M.A., et al.: “Upper abdominal procedures in ad-vanced stage ovarian or primary peritoneal carcinoma patients with minimal or no gross residual disease: an analysis of Gynecologic Oncology Group (GOG) 182”. Gynecol. Oncol., 2013, 130, 487.

[3] Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., Montz F. J.: “Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis”. J. Clin. Oncol., 2002, 20, 1248.

[4] Chi D.S., Eisenhauer E.L., Lang J., Huh J., Haddad L., Abu-Rustum N. R., et al.: “What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?” Gynecol. Oncol., 2006, 103, 559.

[5] Chi D.S., Liao J.B., Leon L.F., Venkatraman E.S., Hensley M.L., Bhaskaran D., Hoskins W.J.: “Identification of prognostic factors in advanced epithelial ovarian carcinoma”. Gynecol. Oncol., 2001, 82, 532.

[6] Winter W.E. 3rd., Maxwell G.L., Tian C., Carlson J.W., Ozols R.F., Rose P.G., et al.: “Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study”. J. Clin. Oncol., 2007, 25, 3621.

[7] Aletti G.D., Dowdy S.C., Gostout B.S., Jones M.B., Stanhope C.R., Wilson T.O., et al.: “Aggressive surgical effort and improved sur-vival in advanced-stage ovarian cancer”. Obstet. Gynecol., 2006, 107, 77.

[8] Chi D.S., Franklin C.C., Levine D.A., Akselrod F., Sabbatini P., Jar-nagin W.R., et al.: “Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach”. Gynecol. Oncol., 2004, 94, 650.

[9] Eisenkop S.M., Spirtos N.M., Friedman R.L., Lin W.C., Pisani AL, Perticucci S.: “Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with ad-vanced ovarian cancer: a prospective study”. Gynecol. Oncol., 2003, 90, 390.

[10] Zivanovic O., Sima C.S., Iasonos A., Hoskins W.J., Pingle P.R., Leitao M.M. Jr., et al.: “The effect of primary cytoreduction on out-comes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum”. Gynecol. Oncol., 2010, 116, 351.

[11] Rustin G.J., Quinn M., Thigpen T., du Bois A., Pujade-Lauraine E., Jakobsen A., et al.: “Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)”. J. Natl. Cancer Inst., 2004, 96, 487.

[12] Eisenhauer E.L., Abu-Rustum N.R., Sonoda Y., Levine D.A., Poynor E. A., Aghajanian C., et al.: “The addition of extensive upper abdom-inal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer”. Gynecol. Oncol., 2006, 103, 1083.

[13] Allen D.G., Heintz A.P., Touw F.W.: “A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary”. Eur. J. Gynaecol. Oncol., 1995, 16, 349.

[14] Magtibay P.M., Adams P.B., Silverman M.B., Cha S.S., Podratz

K. C.: “Splenectomy as part of cytoreductive surgery in ovarian can-cer”. Gynecol. Oncol., 2006, 102, 369.

[15] Chi D.S., Zivanovic O., Levinson K.L., Kolev V., Huh J., Dottino J., et al.: “The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas”. Gynecol. Oncol., 2010, 119, 38.

Kehoe S.M., Eisenhauer E.L., Abu-Rustum N.R., Sonoda Y., D’An-gelica M., Jarnagin W.R., et al.: “Incidence and management of pan-creatic leaks after splenectomy with distal pancreatectomy performed during primary cytoreductive surgery for advanced ovar-ian, peritoneal and fallopian tube cancer”. Gynecol. Oncol., 2009, 112, 496.

[17] Yildirim Y., Sanci M.: “The feasibility and morbidity of distal pan-createctomy in extensive cytoreductive surgery for advanced epithe-lial ovarian cancer”. Arch. Gynecol. Obstet., 2005, 272, 31.

[18] Markman M., Bundy B.N., Alberts D.S., Fowler J.M., Clark-Pearson D. L., Carson L.F., et al.: “Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin fol-lowed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group”. J. Clin. Oncol., 2001, 19, 1001.

[19] Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., et al.: “Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally re-sected stage III ovarian cancer: a Gynecologic Oncology Group study”. J. Clin. Oncol., 2003, 21, 3194.

[20] Crawford S.C., Vasey P.A., Paul J., Hay A., Davis J.A., Kaye S.B.: “Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial”. J. Clin. Oncol., 2005, 23, 8802.

[21] Markman M.: “Concept of optimal surgical cytoreduction in ad-vanced ovarian cancer: a brief critique and a call for action”. J. Clin. Oncol., 2007, 25, 4168.

[22] Eisenkop S.M., Friedman R.L., Wang H.J.: “Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study”. Gynecol. Oncol., 1998, 69, 103.

[23] Hoskins W.J.: “Epithelial ovarian carcinoma: principles of primary surgery”. Gynecol. Oncol., 1994, 55, S91.